54 related articles for article (PubMed ID: 31119479)
21. Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
Jaeckle KA; Anderson SK; Twohy EL; Dixon JG; Giannini C; Jenkins R; Egorin MJ; Sarkaria JN; Brown PD; Flynn PJ; Schwerkoske J; Buckner JC; Galanis E
J Neurooncol; 2019 Jul; 143(3):583. PubMed ID: 31165953
[TBL] [Abstract][Full Text] [Related]
22. The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.
Van Obbergh F; Knoops L; Devos T; Beguin Y; Graux C; Benghiat F; Kargar-Samani K; Bauwens D; Efira A; Dubois C; Springael C; Montfort L; Connerotte T; Capron A; Delannoy A; Wallemacq P
Clin Biochem; 2017 May; 50(7-8):452-454. PubMed ID: 28017570
[TBL] [Abstract][Full Text] [Related]
23. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
Louis DN; Perry A; Reifenberger G; von Deimling A; Figarella-Branger D; Cavenee WK; Ohgaki H; Wiestler OD; Kleihues P; Ellison DW
Acta Neuropathol; 2016 Jun; 131(6):803-20. PubMed ID: 27157931
[TBL] [Abstract][Full Text] [Related]
24. Response to imatinib as a function of target kinase expression in recurrent glioblastoma.
Hassler MR; Vedadinejad M; Flechl B; Haberler C; Preusser M; Hainfellner JA; Wöhrer A; Dieckmann KU; Rössler K; Kast R; Marosi C
Springerplus; 2014; 3():111. PubMed ID: 25674429
[TBL] [Abstract][Full Text] [Related]
25. Antagonistic modulation of gliomagenesis by Pax6 and Olig2 in PDGF-induced oligodendroglioma.
Appolloni I; Calzolari F; Barilari M; Terrile M; Daga A; Malatesta P
Int J Cancer; 2012 Oct; 131(7):E1078-87. PubMed ID: 22514120
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Gururangan S; Peters KB; McLendon R; Sathornsumetee S; Rich JN; Lipp ES; Janney D; Friedman HS
Cancer; 2012 Oct; 118(19):4759-67. PubMed ID: 22371319
[TBL] [Abstract][Full Text] [Related]
27. Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma.
Doucette T; Yang Y; Zhang W; Fuller GN; Suki D; Fults DW; Rao G
Int J Cancer; 2011 Nov; 129(9):2093-103. PubMed ID: 21171016
[TBL] [Abstract][Full Text] [Related]
28. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
29. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
Reardon DA; Dresemann G; Taillibert S; Campone M; van den Bent M; Clement P; Blomquist E; Gordower L; Schultz H; Raizer J; Hau P; Easaw J; Gil M; Tonn J; Gijtenbeek A; Schlegel U; Bergstrom P; Green S; Weir A; Nikolova Z
Br J Cancer; 2009 Dec; 101(12):1995-2004. PubMed ID: 19904263
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
31. In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation.
Ranza E; Mazzini G; Facoetti A; Nano R
J Neurooncol; 2010 Feb; 96(3):349-57. PubMed ID: 19629393
[TBL] [Abstract][Full Text] [Related]
32. Imatinib is a substrate for various multidrug resistance proteins.
Czyzewski K; Styczynski J
Neoplasma; 2009; 56(3):202-7. PubMed ID: 19309222
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells.
Shingu T; Fujiwara K; Bögler O; Akiyama Y; Moritake K; Shinojima N; Tamada Y; Yokoyama T; Kondo S
Int J Cancer; 2009 Mar; 124(5):1060-71. PubMed ID: 19048625
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Raymond E; Brandes AA; Dittrich C; Fumoleau P; Coudert B; Clement PM; Frenay M; Rampling R; Stupp R; Kros JM; Heinrich MC; Gorlia T; Lacombe D; van den Bent MJ;
J Clin Oncol; 2008 Oct; 26(28):4659-65. PubMed ID: 18824712
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Desjardins A; Quinn JA; Vredenburgh JJ; Sathornsumetee S; Friedman AH; Herndon JE; McLendon RE; Provenzale JM; Rich JN; Sampson JH; Gururangan S; Dowell JM; Salvado A; Friedman HS; Reardon DA
J Neurooncol; 2007 May; 83(1):53-60. PubMed ID: 17245623
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetics of imatinib.
Peng B; Lloyd P; Schran H
Clin Pharmacokinet; 2005; 44(9):879-94. PubMed ID: 16122278
[TBL] [Abstract][Full Text] [Related]
38. The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats.
Dai C; Lyustikman Y; Shih A; Hu X; Fuller GN; Rosenblum M; Holland EC
Neoplasia; 2005 Apr; 7(4):397-406. PubMed ID: 15967117
[TBL] [Abstract][Full Text] [Related]
39. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
Leis JF; Stepan DE; Curtin PT; Ford JM; Peng B; Schubach S; Druker BJ; Maziarz RT
Leuk Lymphoma; 2004 Apr; 45(4):695-8. PubMed ID: 15160941
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
